ReviewFrontiers in cardiovascular medicine2025
The role of Nrf2 signaling pathway in diabetic cardiomyopathy: from pathogenesis to traditional Chinese medicine interventions.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Melatonin Attenuates Glucolipotoxicity-Induced Cardiac Oxidative Stress, Inflammation, Pyroptosis, and Fibrotic Remodeling in STZ/HFD-Treated ApoEAntioxidants (Basel, Switzerland) · 2026Article
- Cardiac-restricted Nrf2 activation blocks diabetic cardiomyopathy via Akt-driven glycolysis and AMPK-PGC-1α fatty-acid oxidation.Acta diabetologica · 2026Article
- Novel therapeutic strategies targeting mitochondrial quality control for metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM), a common diabetic complication independent of hypertension, coronary heart disease and heart valve disease is a major cause of cardiovascular mortality. The pathogenesis of DCM is complex. The Nrf2-related signaling pathway which regulates oxidative stress, energy metabolism and mitochondrial physiology may play important role in the pathogenesis of DCM. Current treatments for DCM focus on blood glucose and pressure control, cardiovascular protection, lipid lowering and blockade of the renin-angiotensin system. However, the adverse drug reactions are inevitable. Traditional Chinese medicine (TCM) as a multi-target, multi-pathway treatment approach is considered to be a promising therapy for DCM. We reviewed how the Nrf2 and related signaling pathway regulated pathophysiological processes such as oxidative stress, inflammation, myocardial fibrosis, apoptosis, ferroptosis, autophagy and mitochondrial dysfunction in the progression of DCM and explored the potential mechanism and clinical value of TCM in DCM treatment. Based on a literature review, we found that various herbal compounds and combinations could alleviate DCM via the Nrf2 signaling pathway. This review highlighted the role of the Nrf2 signaling pathway in DCM progression and put forward new therapeutic strategies for DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.